Qualigen Therapeutics, Inc. Amends Secured Demand Promissory Note

On September 15, 2025, Qualigen Therapeutics, Inc. entered into Amendment No. 1 to the Amended and Restated Secured Demand Promissory Note with Marizyme, Inc. The amendment corrects the maturity date to August 21, 2026, increases the advance and corresponding principal amount by $75,000, resulting in a revised outstanding principal balance of $4,526,462.18, and reaffirms that the Company’s obligations remain secured under the existing Security Agreement. The additional advance accrues interest at the rate set forth in the Amended and Restated Note. This amendment is a significant financial obligation for the Company and reflects ongoing financial arrangements with Marizyme, Inc.